Objective: Evaluation of hyperchromatic crowded groups in Papanicolaou (Pap) tests from women during menstruation can be a diagnostic pitfall due to similar morphological appearances with significant cervical lesions. We studied the results of p16INK4a and ProEx C on cell blocks from Pap tests during menstruation in an attempt to facilitate the differentiation. Study Design: Immunohistochemical stains for p16INK4a and ProEx C were performed on 25 cell blocks prepared from residual liquid-based cervical material with menstrual contamination. Results: Strong, diffuse, and full thickness staining pattern for p16INK4a and ProEx C was observed in cases of high-grade squamous intraepithelial lesion (HSIL) and small cell carcinoma of the cervix. The low-grade squamous intraepithelial lesion cases and cases negative for intraepithelial lesion or malignancy were negative for ProEx C, with focal staining for p16INK4a. The benign endometrial cells had either negative or focal patchy staining, which is often associated with tubal metaplasia. Conclusion: p16INK4a and ProEx C are sensitive markers for identifying significant lesions in Pap test specimens with menstrual contamination. Patchy/mosaic staining may be seen in benign endometrial tissue with tubal metaplasia, but strong, diffuse staining likely indicates HSIL or carcinoma. These findings can be helpful in interpreting hyperchromatic crowded groups in menstrual Pap specimens. Further study may be prudent, being aware of the small study group.

Keywords:
Cervical cancer, Hyperchromatic crowded group, Menstrual contamination, Papanicolaou tests, Squamous intraepithelial lesion
1.
Chivukula M, Austin RM, Shidham VB: Evaluation and significance of hyperchromatic crowded groups (HCG) in liquid-based paps. Cytojournal 2007;4:2.
2.
Gupta N, Srinivasan R, Rajwanshi A: Functional biomarkers in cervical precancer: an overview. Diagn Cytopathol 2009;38:618–623.
3.
Risse EK, Ouwerkerk-Noordam E, Boon ME: Endometrial cells in liquid-based cervical cytology: a diagnostic pitfall solved by preparing cytohistology from the residual thin layer sample. Acta Cytol 2011;55:327–333.
4.
Samarawardana P, Dehn DL, Singh M, Franquemont D, Thompson C, Gaido L, Torkko KC, Homer P, Burke S, Titmus MA, Nayi V, Shroyer KR: p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol 2010;118:146–156.
5.
Tringler B, Gup CJ, Singh M, Groshong S, Shroyer AL, Heinz DE, Shroyer KR: Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004;35:689–696.
6.
Negri G, Egarter-Vigl E, Kasal A, Romano F, Haitel A, Mian C: p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations. Am J Surg Pathol 2003;27:187–193.
7.
Eleuterio J Jr, Giraldo PC, Goncalves AK, Cavalcante DI, de Almeida Ferreira FV, Mesquita SM, Morais SS: Prognostic markers of high-grade squamous intraepithelial lesions: the role of p16INK4a and high-risk human papillomavirus. Acta Obstet Gynecol Scand 2007;86:94–98.
8.
Keating JT, Cviko A, Riethdorf S, Riethdorf L, Quade BJ, Sun D, Duensing S, Sheets EE, Munger K, Crum CP: Ki-67, cyclin E, and p16INK4 are complimentary surrogate biomarkers for human papilloma virus-related cervical neoplasia. Am J Surg Pathol 2001;25:884–891.
9.
Qiao X, Bhuiya TA, Spitzer M: Differentiating high-grade cervical intraepithelial lesion from atrophy in postmenopausal women using Ki-67, cyclin E, and p16 immunohistochemical analysis. J Low Genit Tract Dis 2005;9:100–107.
10.
Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, Dallenbach-Hellweg G, Schmidt D, von Knebel Doeberitz M: Overexpression of p16INK4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276–284.
11.
Badr RE, Walts AE, Chung F, Bose S: BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 2008;32:899–906.
12.
Conesa-Zamora P, Domenech-Peris A, Orantes-Casado FJ, Ortiz-Reina S, Sahuquillo-Frias L, Acosta-Ortega J, Garcia-Solano J, Perez-Guillermo M: Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol 2009;132:378–390.
13.
Conesa-Zamora P, Domenech-Peris A, Ortiz-Reina S, Orantes-Casado FJ, Acosta-Ortega J, Garcia-Solano J, Perez-Guillermo M: Immunohistochemical evaluation of ProEx C in human papillomavirus-induced lesions of the cervix. J Clin Pathol 2009;62:159–162.
14.
Halloush RA, Akpolat I, Jim Zhai Q, Schwartz MR, Mody DR: Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer 2008;114:474–480.
15.
Akpolat I, Smith DA, Ramzy I, Chirala M, Mody DR: The utility of p16INK4a and Ki-67 staining on cell blocks prepared from residual thin-layer cervicovaginal material. Cancer 2004;102:142–149.
16.
Keyhani-Rofagha S, Vesey-Shecket M: Diagnostic value, feasibility, and validity of preparing cell blocks from fluid-based gynecologic cytology specimens. Cancer 2002;96:204–209.
17.
Yang GC, Wan LS, Papellas J, Waisman J: Compact cell blocks. Use for body fluids, fine needle aspirations and endometrial brush biopsies. Acta Cytol 1998;42:703–706.
18.
Narine N, Rana DN, McVey RJ, Fitzmaurice R: Ancillary testing in liquid based cytology to distinguish cervical glandular neoplasia from tuboendometrial metaplasia in a young woman. Diagn Cytopathol 2010;38:828–832.
19.
Demay RM: Hyperchromatic crowded groups: pitfalls in pap smear diagnosis. Am J Clin Pathol 2000;114(suppl):S36–S43.
20.
Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, Malamou-Mitsi V, Paraskevaidis E: p16INK4A immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev 2009;35:210–220.
21.
Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol 2010;34:915–926.
22.
Bohn OL, Fuertes-Camilo M, Navarro L, Saldivar J, Sanchez-Sosa S: p16INK4a expression in basal-like breast carcinoma. Int J Clin Exp Pathol 2010;3:600–607.
23.
Geradts J, Wilson PA: High frequency of aberrant p16INK4A expression in human breast cancer. Am J Pathol 1996;149:15–20.
24.
Horree N, Heintz AP, Sie-Go DM, van Diest PJ: p16 is consistently expressed in endometrial tubal metaplasia. Cell Oncol 2007;29:37–45.
25.
Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH: Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol 2010;34:1077–1087.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.